Overview

End-stage Renal Disease (ESRD) Pilot Study

Status:
Completed
Trial end date:
2021-09-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer